Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHPA NDAC nomination

This article was originally published in The Tan Sheet

Executive Summary

CHPA nominates George Goldstein, MD, to represent the industry on FDA's Nonprescription Drugs Advisory Committee, the organization states in a Nov. 28 letter to FDA. The Consumer Healthcare Products Association polled members to identify Goldstein as the "consensus candidate" for industry representative. Goldstein comes to the table with a resume that includes 14 years in private practice as a pediatrician and 15 years with Sterling Drug, according to CHPA. Goldstein served as Chief Medical Officer for Sterling's OTC division, Glenbrook Labs, as well as for the Rx division, Winthrop Labs. FDA announced in November that it was taking nominations for a non-voting industry representative to serve on the committee ("The Tan Sheet" Nov. 21, 2005, In Brief)...

You may also be interested in...

NDAC nominations

Nominations for a non-voting industry representative to serve on the Nonprescription Drugs Advisory Committee must be received by FDA no later than Dec. 15, the agency announces in the Nov. 15 Federal Register. Industry organizations interested in participating in the member's selection should notify FDA by letter. The agency will compile a list of nominees by Dec. 15 and will forward the list to participating organizations. A candidate must be selected by participants within 60 days of receipt of the FDA letter. If no candidate is chosen, the FDA commissioner will select the non-voting member, FDA notes. Self-nominations are acceptable and organizations may submit multiple nominations...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts